Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Strategy of Allogeneic and Autologous Cancer Vaccines Publisher



Valilou SF1 ; Rezaei N2, 3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2018


Abstract

Various clinical trials have been conducted to test autologous and allogeneic vaccines for treatment of different types of cancer. Autologous cancer vaccines include unique or rare tumor antigens that develop through mutational events. Allogeneic cancer vaccines, on the other hand, are comprised of intact or modified cancer cells from other patients selected for the presence of shared antigens found on a large percentage of similar tumor types. Their significant advantages are their availability for patients in all stages of the disease and provide the capability to administer multiple vaccinations over a protracted period. Until now, many clinical trials have been conducted but because of great heterogeneity present inter- and intratumorally, few positive results have been attained. In this chapter, we will provide brief definitions of both allogeneic and autologous cancer vaccines and discuss various clinical studies for each of the cancer types. © 2019 Nima Rezaei and Mahsa Keshavarz-Fathi Published by Elsevier Ltd All rights reserved.
Related Docs
1. Strategy of Allogeneic and Autologous Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
2. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
3. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
Experts (# of related papers)
Nima Rezaei (2)